Illumina Inc. (ILMN) reported fourth-quarter 2023 adjusted earnings per share (EPS) of 14 cents, beating the Zacks Consensus Estimate of 1 cent by a considerable margin. The bottom line matched the year-ago quarter’s figure.The adjustments exclude the impact of GRAIL pre-acquisition net operating losses on GILTI, the utilization of U.S. foreign tax credits and incremental non-GAAP tax expenses, among others. Including one-time items, the company’sGAAP loss per share was $1.11 compared with the year-ago quar ...

Illumina (ILMN) reported $1.12 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 3.6%. EPS of $0.14 for the same period compares to $0.14 a year ago.The reported revenue represents a surprise of +3.11% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $0.01, the EPS surprise was +1300.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis) Shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023 GAAP diluted loss per share of $(1.11) for Q4 2023, compared to GAAP diluted loss per share of $(0.89) for Q4 2022 Non-GAAP diluted earnings per share of $0.14 for both Q4 2023 and Q4 2022 GAAP diluted loss per share of ...

AUSTIN, Texas & MENLO PARK, Calif.--(BUSINESS WIRE)--Curative Insurance Company, a pioneering healthcare services company, and GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced the availability of Galleri®, a multi-cancer early detection (MCED) screening test to eligible insurance plan members. The Galleri test will be available to all members, across all plan types, who are over the age of 50 and to all other members with risk factors for develop ...

Illumina, Inc. (ILMN) announced preliminary financial results for fourth-quarter and full-year 2023 on Jan 9. Following this release, shares of the company lost 1.2% till the last trading session on Jan 12.The company is scheduled to release fourth-quarter results on Feb 8, after the closing bell.Prelim Q4 in DetailPer the preliminary release, fourth-quarter 2023 consolidated revenues are likely to be $ $1,115 million, up 3% year over year. The Zacks Consensus Estimate is pegged at $1.10 billion.Core Illumi ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Illumina® Ventures Labs, an early-stage company creation and investment engine with fully equipped genomics labs based in Foster City, CA and Cambridge, UK, is now operational and finalizing agreements with several startup companies. Illumina Ventures Labs is part of Illumina Ventures, the premier genomics and precision health venture firm supporting early-stage companies transforming healthcare and our world. With its extensive sequencing capabilities and state-of-the- ...

MENLO PARK, Calif., & TAMPA, Fla.--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and BeniComp, a customized health plan provider, today announced the availability of Galleri®, a multi-cancer early detection (MCED) screening test, to eligible patients initially through BeniComp Select members. This partnership underscores BeniComp’s commitment to proactive and preventive health management, enabling an even broader reach of their transformative ...

Illumina, Inc. (NASDAQ:ILMN) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 12:00 PM ET Company Participants Jacob Thaysen - CEO Joydeep Goswami - CFO, Chief Strategy and Corporate Development Officer Conference Call Participants Rachel Vatnsdal - J.P. Morgan Rachel Vatnsdal Perfect. Good morning, everyone. This is Rachel Vatnsdal with the Life Science Tools and Diagnostics team, I'm here with Illumina up on stage. So as these sessions are, it's going to be 40 minutes, roughly 20 minutes of p ...

SAN DIEGO, Jan. 9, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2023 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 at 9:00am Pacific Time (12:00pm Eastern Time). The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. Preliminary financial results Consolidated revenue of ap ...

Shares of gene sequencing leader Illumina (ILMN 2.44%) rallied 36.6% in December, according to data from S&P Global Market Intelligence.Investors might not be quite so excited, as Illumina entered the month more than 80% below its all-time highs from 2021. But hopes for a bottoming and recovery surfaced in December, as Illumina received several positive analyst notes, and activist investor Carl Icahn made his next move in shaking up the company's board of directors.Is the company at the start of its recover ...